Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Johnson and Johnson
Dow
Merck
Colorcon
Medtronic
Mallinckrodt

Last Updated: October 19, 2019

DrugPatentWatch Database Preview

Claims for Patent: 8,206,748

See Plans and Pricing

« Back to Dashboard

Summary for Patent: 8,206,748
Title:Powdery composition for nasal administration
Abstract: A powdery composition for nasal administration, where (1) the composition contains (i) a drug, (ii) a water-absorbing and gel-forming base material such as hydroxypropyl cellulose or hydroxypropylmethyl cellulose and (iii) a water-absorbing and water-insoluble base material such as crystalline cellulose or .alpha.-cellulose, (2) wherein the amount of the water-absorbing and gel-forming base material is about 5-40 wt % based on the total of the water-absorbing and gel-forming base material and the water-absorbing and water-insoluble base material, and (3) wherein the drug is unevenly dispersed more on/in the water-absorbing and water-insoluble base material than on/in the water-absorbing and gel-forming base material.
Inventor(s): Dohi; Masahiko (Tokyo, JP), Nishibe; Yoshihisa (Tokyo, JP), Makino; Yuji (Tokyo, JP), Fujii; Takao (Tokyo, JP)
Assignee: Teijin Limited (Osaka, JP)
Application Number:12/610,901
Patent Claims:1. A powdery composition for nasal administration comprising (i) a drug, (ii) one or more of a water-absorbing and gel-forming base material selected from the group consisting of hydroxypropyl cellulose, hydroxypropylmethyl cellulose, methyl cellulose, hydroxyethyl cellulose, and sodium carboxymethyl cellulose and (iii) one or more of a water-absorbing and water-insoluble base material selected from the group consisting of crystalline cellulose, .alpha.-cellulose, cross-linked sodium carboxy-methyl cellulose, cross-linked starch, chitin and chitosan, wherein the content of the water-absorbing and gel-forming base material is about 5-40 wt% based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material, 70 wt % or more based on the drug is dispersed on or in the water-absorbing and water-insoluble base material and on or in the water-absorbing and gel-forming base material, the water-absorbing and water-insoluble base material and water-absorbing and gel-forming base material comprise particles, wherein the drug is dispersed more on or in the water-absorbing and water-insoluble base material than on or in the water-absorbing and gel-forming base material, wherein the powdery composition is obtained by a method comprising making an average particle diameter of the water-absorbing and water-insoluble base material larger than an average particle diameter of the water-absorbing and gel-forming base material, and wherein the water-absorbing and water-insoluble base material has an average particle diameter of 50-350 .mu.m in at least 90 wt % based on the water-absorbing and water-insoluble particles, and the water-absorbing and gel-forming base material has an average particle diameter of 10-100 .mu.m in at least 90 wt % based on the water-absorbing and gel-forming particles.

2. A powdery composition for nasal administration according to claim 1, wherein the water-absorbing and water-insoluble base material has an average particle diameter of 100-250 .mu.m in at least 90 wt % based on the water-absorbing and water-insoluble particles, and the water-absorbing and gel-forming base material has an average particle diameter of 20-50 .mu.m in at least 90 wt % based on the water-absorbing and gel forming particles.

3. A powdery composition for nasal administration according to claim 1, wherein the drug is selected from the group consisting of non-peptide/non-proteinaceous drugs and peptide/proteinaceous drugs having molecular weight of 30,000 or less.

4. A powdery composition for nasal administration according to claim 2, wherein the drug is selected from the group consisting of non-peptide/non-proteinaceous drugs and peptide/proteinaceous drugs having molecular weight of 30,000 or less.

5. A powdery composition for nasal administration according to claim 3, wherein the non-peptide/non-proteinaceous drug is one or more drugs selected from the group consisting of anti-inflammatory steroids, nonsteroidal antiinflammatory drugs, analgesic anti-inflammatory agents, antitussive expectorants, antihistaminic agents, antiallergic drugs, antiemetic drugs, hypnotics, vitamin preparations, sex steroid hormones, antineoplastic drugs, antiarrhythmic drugs, antihypertensive drugs, antianxiety drugs, psychotropic drugs, antiulcer drugs, cardiotonics, analgesics, bronchodilators, treating agents for obesity, antithrombotic drugs, antidiabetic drugs, muscle relaxants and anti-rheumatics.

6. A powdery composition for nasal administration according to claim 4, wherein the non-peptide/non-proteinaceous drug is one or more drugs selected from the group consisting of anti-inflammatory steroids, nonsteroidal antiinflammatory drugs, analgesic anti-inflammatory agents, antitussive expectorants, antihistaminic agents, antiallergic drugs, antiemetic drugs, hypnotics, vitamin preparations, sex steroid hormones, antineoplastic drugs, antiarrhythmic drugs, antihypertensive drugs, antianxiety drugs, psychotropic drugs, antiulcer drugs, cardiotonics, analgesics, bronchodilators, treating agents for obesity, antithrombotic drugs, antidiabetic drugs, muscle relaxants and anti-rheumatics.

7. A powdery composition for nasal administration according to claim 3, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of luteinizing hormone-releasing hormones, growth hormone-releasing factors, somatostatins, vasopressins, oxytocins, hirudins, enkephalins, adrenocorticotropic hormones, bradykinins, calcitonins, insulins, glucagons, growth hormones, growth hormone-releasing hormones, luteinizing hormones, insulin-like growth factors, calcitonin gene-related peptides, atrial natriuretic polypeptides, interferons, erythropoietin, granulocyte colony forming-stimulating factor, macrophage forming-stimulating factor, parathyroid hormones, parathyroid hormone-releasing hormone, prolactin, thyroid-stimulating hormone-releasing hormone and angiotensins.

8. A powdery composition for nasal administration according to claim 4, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of luteinizing hormone-releasing hormones, growth hormone-releasing factors, somatostatins, vasopressins, oxytocins, hirudins, enkephalins, adrenocorticotropic hormones, bradykinins, calcitonins, insulins, glucagons, growth hormones, growth hormone-releasing hormones, luteinizing hormones, insulin-like growth factors, calcitonin gene-related peptides, atrial natriuretic polypeptides, interferons, erythropoietin, granulocyte colony forming-stimulating factor, macrophage forming-stimulating factor, parathyroid hormones, parathyroid hormone-releasing hormone, prolactin, thyroid-stimulating hormone-releasing hormone and angiotensins.

9. A powdery composition for nasal administration according to claim 1, wherein the drug is a peptide/proteinaceous drug having a molecular weight of 500-1500, and the amount of the water-absorbing and gel-forming base material is about 5-30 wt % based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material.

10. A powdery composition for nasal administration according to claim 2, wherein the drug is a peptide/proteinaceous drug having a molecular weight of 500-1500, and the amount of the water-absorbing and gel-forming base material is about 5-30 wt % based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material.

11. A powdery composition for nasal administration according to claim 9, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of vasopressins, luteinizing hormone-releasing hormones, growth hormone-releasing factors, somatostatins, oxytocins, hirudins, enkephalins, adrenocorticotropic hormones and bradykinins.

12. A powdery composition for nasal administration according to claim 10, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of vasopressins, luteinizing hormone-releasing hormones, growth hormone-releasing factors, somatostatins, oxytocins, hirudins, enkephalins, adrenocorticotropic hormones and bradykinins.

13. A powdery composition for nasal administration according to claim 1, wherein the drug is a peptide/proteinaceous drug having a molecular weight of 1500-30,000 and the amount of the water-absorbing and gel-forming base material is about 5-20 wt % based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material.

14. A powdery composition for nasal administration according to claim 2, wherein the drug is a peptide/proteinaceous drug having a molecular weight of 1500-30,000 and the amount of the water-absorbing and gel-forming base material is about 5-20 wt % based on the total of the water-absorbing and water-insoluble base material and the water-absorbing and gel-forming base material.

15. A powdery composition for nasal administration according to claim 13 wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of calcitonins, insulins, glucagons, growth hormones, growth hormone-releasing hormones, luteinizing hormones, insulin-like growth factors, calcitonin gene-related peptides, atrial natriuretic polypeptides, interferons, erythropoietin, granulocyte colony-stimulating factor, macrophage-stimulating factor, parathyroid hormones, parathyroid hormone-releasing hormone, prolactin, thyroid-stimulating hormone-releasing hormone and angiotensins.

16. A powdery composition for nasal administration according to claim 14, wherein the peptide/proteinaceous drug is one or more drugs selected from the group consisting of calcitonins, insulins, glucagons, growth hormones, growth hormone-releasing hormones, luteinizing hormones, insulin-like growth factors, calcitonin gene-related peptides, atrial natriuretic polypeptides, interferons, erythropoietin, granulocyte colony-stimulating factor, macrophage-stimulating factor, parathyroid hormones, parathyroid hormone-releasing hormone, prolactin, thyroid-stimulating hormone-releasing hormone and angiotensins.

17. A powdery composition for nasal administration according to claim 1, wherein the water-absorbing and water-insoluble base material is crystalline cellulose.

18. A powdery composition for nasal administration according to claim 2, wherein the water-absorbing and water-insoluble base material is crystalline cellulose.

19. A powdery composition for nasal administration according to claim 1, wherein the water-absorbing and gel-forming base material is hydroxypropyl cellulose.

20. A powdery composition for nasal administration according to claim 2, wherein the water-absorbing and gel-forming base material is hydroxypropyl cellulose.

21. A powdery composition for nasal administration according to claim 19, wherein the hydroxypropyl cellulose has a viscosity of 150-4000 cps in 2% aqueous solution.

22. A powdery composition for nasal administration according to claim 20, wherein the hydroxypropyl cellulose has a viscosity of 150-4000 cps in 2% aqueous solution.

Summary for Patent:   Start Trial

Foriegn Application Priority Data
Foreign Country Foreign Patent Number Foreign Patent Date
Japan8-39553Feb 27, 1996
Japan8-41079Feb 28, 1996

Details for Patent 8,206,748

Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 001 2015-01-23   Start Trial Teijin Limited (Osaka, JP) 2016-02-27 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 002 2015-01-23   Start Trial Teijin Limited (Osaka, JP) 2016-02-27 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 003 2015-01-23   Start Trial Teijin Limited (Osaka, JP) 2016-02-27 RX Orphan search
Nps Pharms Inc NATPARA parathyroid hormone INJECTABLE;INJECTION 125511 004 2015-01-23   Start Trial Teijin Limited (Osaka, JP) 2016-02-27 RX Orphan search
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Harvard Business School
Mallinckrodt
Dow
Merck
Baxter
AstraZeneca

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.